BR112021026812A2 - Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos - Google Patents
Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmosInfo
- Publication number
- BR112021026812A2 BR112021026812A2 BR112021026812A BR112021026812A BR112021026812A2 BR 112021026812 A2 BR112021026812 A2 BR 112021026812A2 BR 112021026812 A BR112021026812 A BR 112021026812A BR 112021026812 A BR112021026812 A BR 112021026812A BR 112021026812 A2 BR112021026812 A2 BR 112021026812A2
- Authority
- BR
- Brazil
- Prior art keywords
- psma
- ligands
- specific membrane
- membrane antigen
- prostate specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026812A2 true BR112021026812A2 (pt) | 2022-02-22 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026812A BR112021026812A2 (pt) | 2019-07-02 | 2020-06-30 | Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (https=) |
| EP (1) | EP3993837A1 (https=) |
| JP (2) | JP7805170B2 (https=) |
| KR (1) | KR20220044496A (https=) |
| CN (3) | CN120441497A (https=) |
| AR (1) | AR119331A1 (https=) |
| AU (3) | AU2020299974A1 (https=) |
| BR (1) | BR112021026812A2 (https=) |
| CA (1) | CA3144557A1 (https=) |
| CL (1) | CL2021003525A1 (https=) |
| CO (1) | CO2021017708A2 (https=) |
| IL (1) | IL289039B1 (https=) |
| MX (1) | MX2022000136A (https=) |
| PH (1) | PH12021553284A1 (https=) |
| TW (1) | TW202114742A (https=) |
| WO (1) | WO2021001360A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330278A1 (en) * | 2020-04-29 | 2023-10-19 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
| KR20260040237A (ko) | 2023-07-21 | 2026-03-24 | 노파르티스 아게 | Psma 표적 방사성 리간드 치료 요법 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271026A1 (en) | 2000-07-11 | 2002-01-21 | Bml, Inc. | Remedies for bone diseases |
| WO2013022797A1 (en) * | 2011-08-05 | 2013-02-14 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| HRP20240215T1 (hr) * | 2016-03-22 | 2024-04-26 | The Johns Hopkins University | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| KR20250126870A (ko) * | 2018-02-06 | 2025-08-25 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039B1/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230226227A1 (en) | 2023-07-20 |
| AU2024200850B2 (en) | 2025-09-04 |
| CN120441497A (zh) | 2025-08-08 |
| TW202114742A (zh) | 2021-04-16 |
| JP7805170B2 (ja) | 2026-01-23 |
| PH12021553284A1 (en) | 2022-08-01 |
| AU2024200850A1 (en) | 2024-02-29 |
| JP2022538478A (ja) | 2022-09-02 |
| JP2025165975A (ja) | 2025-11-05 |
| CN120441498A (zh) | 2025-08-08 |
| IL289039B1 (en) | 2026-03-01 |
| AU2025271182A1 (en) | 2025-12-18 |
| IL289039A (en) | 2022-02-01 |
| CL2021003525A1 (es) | 2022-10-21 |
| CA3144557A1 (en) | 2021-01-07 |
| CN114341118A (zh) | 2022-04-12 |
| KR20220044496A (ko) | 2022-04-08 |
| MX2022000136A (es) | 2022-04-27 |
| EP3993837A1 (en) | 2022-05-11 |
| AU2020299974A1 (en) | 2022-01-27 |
| AR119331A1 (es) | 2021-12-09 |
| CO2021017708A2 (es) | 2022-05-20 |
| WO2021001360A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026812A2 (pt) | Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos | |
| CO2023004252A2 (es) | Anticuerpos anti-ceacam5 y conjugados y usos de los mismos | |
| BR112022009938A2 (pt) | Compostos macrocíclicos substituídos e métodos de tratamento relacionados | |
| MX2020006112A (es) | Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. | |
| AR110056A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| BR112022001520A2 (pt) | Complexo de peptídeos bicíclicos em heterotandem | |
| CO2021009053A2 (es) | Inhibidores de apol1 y sus métodos de uso | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| CL2009001065A1 (es) | Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros. | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| CR11179A (es) | Anticuerpos humanizados contra el globometro ab (20-42) y sus usos | |
| NZ739770A (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| CY1107294T1 (el) | Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες | |
| MX2025012087A (es) | Piridazinonas y metodos de uso de estas | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| BR112022005026A2 (pt) | Conjugados terapêuticos | |
| CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
| NO341574B1 (no) | Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode. | |
| DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
| PE20200866A1 (es) | Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso | |
| CO2021014748A2 (es) | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo | |
| EA201891473A1 (ru) | Комбинированная терапия | |
| BR112021023595A2 (pt) | Formulações de agentes de imagem de psma | |
| WO2018189661A3 (en) | Methods and compounds for treating diabetes | |
| MX2022000654A (es) | Sistemas fluorescentes para imagenes biologicas y usos de los mismos. |